Winbp MT 25 Tablet ER is a combination antihypertensive medication containing Olmesartan Medoxomil 20 mg and Metoprolol Succinate 25 mg in an extended-release formulation. Olmesartan Medoxomil is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, leading to vasodilation, reduced secretion of aldosterone, and decreased blood pressure. Metoprolol Succinate is a cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, myocardial contractility, and cardiac output, thereby lowering blood pressure and decreasing myocardial oxygen demand. The extended-release formulation ensures a steady plasma concentration, enhancing patient compliance and therapeutic efficacy. Winbp MT 25 Tablet ER is indicated for the management of hypertension, particularly in patients requiring dual therapy to achieve optimal blood pressure control. It may also be beneficial in patients with concomitant cardiovascular conditions such as ischemic heart disease or heart failure where beta-blockade is indicated. Dosage should be individualized based on patient response and tolerability. Caution is advised in patients with bradycardia, heart block, or severe hepatic impairment. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy. This combination therapy offers a synergistic approach to hypertension management, improving cardiovascular outcomes.